You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 14, 2021

New Draft Regulations on Medical Device Management in Vietnam

Subscribe to Updates

Since 2016, the government of Vietnam has issued a number of legal documents on medical device management, including Decree No. 36/2016/ND-CP dated May 15, 2016; Decree No. 169/ND-CP dated December 31, 2018; and Decree No. 03/2020/ND-CP dated January 1, 2020; all of which are concurrently valid. In an effort to unify and streamline regulations on the management of medical devices in Vietnam, the Ministry of Health (MOH) recently developed the draft of a new decree intended to replace the three decrees above. The draft is expected to be submitted to the government for further opinion and approval in the near future.

Below are some highlights of the new draft:

1. Clinical Trials of Medical Devices

The draft adds new regulations on clinical trials of medical devices. In particular, medical device trials will include three phases, in which phases 1 and 2 need to be finished before product registration while phase 3 will be conducted after the medical devices are approved for circulation following the specific requirement from the authorities. This regulation aims to continue evaluating the safety and efficacy of medical devices after they are widely used in the community in line with their usage conditions.

The draft also specifically stipulates cases (i) requiring full-stage clinical trials, (ii) being exempted from some stages of clinical trials, and (iii) being entirely exempted from clinical trials. The full exemption is intended to be applicable to class-A medical devices and medical devices that are already approved for circulation in at least one country in the world, and have sufficient safety and efficacy data.

Also, the draft sets out provisions on the requirements and obligations of relevant entities (the owners of the medical devices that need to be clinically evaluated and entities conducting the trials); dossiers for the trial; and procedures and processes to register and approve clinical trial protocols and trial results.

2. Medical Device Circulation

The draft adds two additional cases ((c) and (d) below) that qualify for the quick registration procedure. Accordingly, under the draft, the class-B/C/D medical devices that are subject to the quick registration procedure will include:

  • Products circulated in at least two of the following countries: Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products circulated in Vietnam prior to December 31, 2020, and satisfying both of the following conditions:
    • The product was circulated for at least three years within a period of five years before the submission date.
    • There have been no warnings about the quality or safety of the product.
  • Products granted an import license and circulated in at least two countries in the world, one of which is Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products meeting urgent needs for national defense, security, epidemic prevention and control, and overcoming of consequences of natural disasters and catastrophes, and having no substitutes available on the market.

Further, according to the draft, the MOH’s evaluation timeline will increase – up to 120 days instead of up to 60 days under current regulations. This is to ensure the feasibility of the evaluation.

3. Importation of Ingredients for Medical Device Production

Under the draft, import licenses are not required for medical device raw materials, except for materials containing narcotic substances and precursors.

4. Medical Device Advertisement

Under the draft, the content of medical device advertising must conform with either the dossiers for declaration of applicable standards for class-A medical devices, or the registration dossiers for class-B/C/D medical devices.

In addition, advertising contents will not require approval from the authorities. Instead, the holders of medical device registration numbers or their authorized entities will be responsible for publicly declaring the intended content and form of the advertising on the Medical Equipment Management Portal before conducting the advertising; the declaration for class-A/B medical devices would be applied from July 1, 2021 while the declaration for class-C/D medical devices would be applied from July 1, 2022.

5. Transitional Regulations

The draft sets out the transition mechanisms below:

  • Import licenses for class-B/C/D medical devices granted from 2018 to 2022 will be valid until December 31, 2022.
  • The procedures for obtaining import licenses during the transition period for class-B/C/D IVD medical devices, including reagents, calibrators, and control materials, are newly stipulated; this also means that the current procedures under Circular 47/2010/TT-BYT guiding the export and import of medicines and packaging in direct contact with medicines and Circular 30/2015/TT-BYT on import of medical equipment will be abolished.

 

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

January 5, 2026
On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam. According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity. Some of the key stipulations of Circular 57 are outlined below. Basis for Determining Technical Standards and Quality Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means: Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations; Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and Documentation evidencing compliance provided by the medical device owner. The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions. Classification of Medical Devices Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality. Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam. Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam. Outlook Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027. Holders of medical
Read More
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted
Read More
November 25, 2025
Food safety incidents can emerge without warning, requiring businesses to act swiftly to protect consumers and comply with regulatory obligations. Across Southeast Asia, Thailand, Vietnam, and Indonesia have each developed comprehensive food recall frameworks designed to ensure rapid removal of unsafe products from the market while holding businesses accountable for compliance failures. While these three jurisdictions share common objectives—protecting public health and ensuring food safety—each has crafted distinct regulatory approaches reflecting their unique administrative structures, enforcement priorities, and legal traditions. Understanding these differences is essential for food businesses operating in the region, as recall procedures, timelines, reporting requirements, and penalties vary significantly across borders. This guide, available through the button below, examines the food recall regulations in Indonesia, Thailand, and Vietnam, providing practical guidance on legal requirements, procedural steps, and compliance obligations in each market.
Read More